Literature DB >> 15469676

Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice.

Gerald Richardson1, Lesley Godfrey, Hugh Gravelle, Ian Watt.   

Abstract

BACKGROUND: Hypertension is a major public health concern and, as the population ages, the size of the problem is likely to increase. However, detection rates and treatment of hypertension have been low. The introduction of new guidelines for the detection and treatment of hypertension have been encouraged but without any consideration to their cost-effectiveness. AIM: To assess the potential cost-effectiveness of implementing new guidelines for the treatment of hypertension in general practice. DESIGN OF STUDY: Model examining the incremental costs and effects of the new guidelines compared with the old.
SETTING: A large general practice in north Yorkshire.
METHOD: Two thousand and twenty-three patients reporting for a new health patient check had the costs and outcomes under the old and new guidelines estimated.
RESULTS: Implementing new guidelines for the detection, management, and treatment of hypertension in a primary care setting is more costly than the implementation of previous guidelines, but more effective in reducing the risk of cardiovascular disease. The incremental cost per cardiovascular disease event avoided is ?30 000, although sensitivity analysis shows that the estimate is subject to considerable uncertainty.
CONCLUSIONS: Compared with previous guidelines, introducing new guidelines for the management and treatment of hypertension in new patients in general practice is likely to be cost-effective. However, the workforce implications for general practitioners (GPs) and practice nurses should be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469676      PMCID: PMC1324882     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  13 in total

1.  Discounting for health effects in cost-benefit and cost-effectiveness analysis.

Authors:  H Gravelle; D Smith
Journal:  Health Econ       Date:  2001-10       Impact factor: 3.046

2.  A meta-analysis of outcome trials in elderly hypertensives.

Authors:  L Thijs; R Fagard; P Lijnen; J Staessen; R Van Hoof; A Amery
Journal:  J Hypertens       Date:  1992-10       Impact factor: 4.844

Review 3.  Rule of halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care.

Authors:  J T Hart
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

4.  British Hypertension Society guidelines for hypertension management 1999: summary.

Authors:  L E Ramsay; B Williams; G D Johnston; G A MacGregor; L Poston; J F Potter; N R Poulter; G Russell
Journal:  BMJ       Date:  1999-09-04

Review 5.  Should cholesterol be measured in all hypertensives?

Authors:  I U Haq; W W Yeo; P R Jackson; L E Ramsay
Journal:  J Hum Hypertens       Date:  1995-06       Impact factor: 3.012

Review 6.  Hypertension in the elderly. Implications and generalizability of randomized trials.

Authors:  C D Mulrow; J A Cornell; C R Herrera; A Kadri; L Farnett; C Aguilar
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

7.  The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis.

Authors:  N S Hartunian; C N Smart; M S Thompson
Journal:  Am J Public Health       Date:  1980-12       Impact factor: 9.308

Review 8.  Control of blood pressure in the community: an unsolved problem.

Authors:  Antonio Salvetti; Daniele Versari
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  General practitioners' knowledge of and attitudes to the management of hypertension in elderly patients.

Authors:  T Fahey; C Silagy
Journal:  Br J Gen Pract       Date:  1994-10       Impact factor: 5.386

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

View more
  4 in total

1.  2006 Ontario Survey on the Prevalence and Control of Hypertension (ON-BP): rationale and design of a community-based cross-sectional survey.

Authors:  J George Fodor; Frans H H Leenen; Eftyhia Helis; Penelope Turton
Journal:  Can J Cardiol       Date:  2008-06       Impact factor: 5.223

2.  Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state.

Authors:  Kristin M Conway; Scott D Grosse; Lijing Ouyang; Natalie Street; Paul A Romitti
Journal:  Muscle Nerve       Date:  2022-02-09       Impact factor: 3.852

3.  Physicians' perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study.

Authors:  Mamas Theodorou; Panagiotis Stafylas; Georgia Kourlaba; Daphne Kaitelidou; Nikos Maniadakis; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2012-11-28       Impact factor: 2.420

4.  Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.

Authors:  Neill Booth; Antti Jula; Pasi Aronen; Minna Kaila; Timo Klaukka; Katriina Kukkonen-Harjula; Antti Reunanen; Pekka Rissanen; Harri Sintonen; Marjukka Mäkelä
Journal:  BMC Health Serv Res       Date:  2007-10-24       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.